Nuvectis Halts NXP800 in Ovarian Cancer as Q3 Loss Widens to $30.1M
NVCT has more than doubled off its 52-week low of $5.55 on elevated volume (1.9× avg).
Summary
Nuvectis is stopping further development of NXP800 in ovarian cancer and is looking at other tumor types for the drug. That removes the ovarian indication from the pipeline and puts the program's future on a new, unspecified path. The Q3 print showed $0 revenue and a $30.1 million net loss, or $1.02 per share, versus a $7.5 million loss a year earlier. Cash stood at $140.7 million, the same figure disclosed in yesterday's release and 8-K, following the $115 million July offering. The widened loss and the dropped indication land together, so the market has to reprice both the burn and the pipeline. NXP200 remains the lead story, with expanded Phase 1b data presented at ESMO on October 26 and a Breakthrough Therapy Designation in China for partner Haisco.
At the time of this announcement, NVCT was trading at $19.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $602.9M. The 52-week trading range was $5.55 to $29.28. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.